7Baggers
 moleculin biotech (mbrx) awaits canadian patent for annamycin in  GuruFocus Thu, 25 Sep 2025 14:34:44 GMT
 Moleculin Biotech Secures Canadian Patent for Annamycin  TipRanks Thu, 25 Sep 2025 13:01:13 GMT
 moleculin receives canadian patent allowance for cancer drug annamycin  Investing.com Thu, 25 Sep 2025 12:53:48 GMT
 Moleculin Biotech (MBRX) Files to Sell 64.86 Million Common Shar  GuruFocus Sat, 20 Sep 2025 01:04:44 GMT
 H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock  Investing.com Wed, 10 Sep 2025 07:00:00 GMT
 moleculin biotech accelerates recruitment in phase 3 miracle trial  Yahoo Finance Wed, 10 Sep 2025 07:00:00 GMT
 moleculin biotech begins phase 2b/3 miracle trial enrollment  TipRanks Tue, 09 Sep 2025 08:48:45 GMT
 moleculin biotech expands global phase 2b/3 trial  TipRanks Tue, 09 Sep 2025 07:00:00 GMT
 moleculin expands aml trial sites globally, targets 45 patients by q4  Investing.com Tue, 09 Sep 2025 07:00:00 GMT
 Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment  TipRanks Mon, 08 Sep 2025 07:00:00 GMT
 moleculin enrolls first eu patients in pivotal aml cancer trial  Investing.com Mon, 08 Sep 2025 07:00:00 GMT
 moleculin biotech releases new corporate presentation  TipRanks Mon, 08 Sep 2025 07:00:00 GMT
 moleculin biotech completes promising annamycin trial  MSN Sun, 07 Sep 2025 00:14:39 GMT
 moleculin biotech completes promising annamycin trial  MSN Mon, 01 Sep 2025 16:48:03 GMT
 Moleculin Biotech Secures $6 Million Through Warrant Agreement  TipRanks Fri, 29 Aug 2025 07:00:00 GMT
 us stocks mixed; nvidia posts upbeat earnings  Benzinga Thu, 28 Aug 2025 14:27:31 GMT
 moleculin biotech reports q2 2025 financial results  MSN Thu, 28 Aug 2025 09:47:49 GMT
 moleculin issues new positive aml overall survival data:  GlobeNewswire Thu, 28 Aug 2025 05:30:32 GMT
 Moleculin Issues New Positive AML Overall Survival Data:  GlobeNewswire Wed, 27 Aug 2025 07:00:00 GMT
 Moleculin Biotech Completes Promising Annamycin Trial  TipRanks Wed, 27 Aug 2025 07:00:00 GMT

Moleculin Biotech, Inc
(NASDAQ:MBRX) 

MBRX stock logo

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or r...

Founded: 2015
Full Time Employees: 11
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends